Key facts
- It has raised $3.0M across 3 recorded rounds; the latest was Seed Round ($325K) in Sep 2025.
- Notable investors include US National Science Foundation, United States Department of War, Keiretsu Forum, Center for Life Science Ventures, National Institute on Deafness and Other Communication Disorders — 11 tracked in total.
- Renerva has filed 4 Form Ds with the SEC since 2018, most recently Sep 2025 ($325K sold to 35 investors).
- Status: Privately Held (backing).
Investors
11+- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Renerva
Funding rounds
3 roundsAbout Renerva
Developer of medical device implants intended to offer surgical devices to facilitate nerve repair, recovery, and storage. The company's implants focus on peripheral treatment to improve function, outcome, and accelerate healing, enabling doctors to help patients accelerate healing and return function following nerve injury.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2017
- Employees
- 8
- Website
- renerva.com/
- Ownership
- Privately Held (backing)
Renerva doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Renerva shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Renerva in its N-PORT filings yet. We sweep new filings monthly.